NCT02846519View on ClinicalTrials.gov

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 26, 2016

Primary Completion Date

May 28, 2016

Study Completion Date

May 28, 2016

Conditions
Healthy
Interventions
DRUG

Esketamine

100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.

DRUG

Rifampin

2 capsules (300 mg each) of rifampin.

Trial Locations (1)

Unknown

Cypress

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02846519 - Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine | Biotech Hunter | Biotech Hunter